MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

TransMedics Group Inc

Closed

SectorHealthcare

73.03 7.29

Overview

Share price change

24h

Current

Min

66.95

Max

73.51

Key metrics

By Trading Economics

Income

2.6M

6.9M

Sales

13M

122M

P/E

Sector Avg

64.076

63.778

EPS

0.19

Profit margin

5.638

Employees

728

EBITDA

3.2M

16M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+47.52% upside

Dividends

By Dow Jones

Next Earnings

29 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-280M

2.3B

Previous open

65.74

Previous close

73.03

News Sentiment

By Acuity

90%

10%

369 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

TransMedics Group Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 wrz 2024, 03:29 UTC

Top News

Dow Jones Futures: Meta, Apple, Tesla Lead New Buys In Big Rally. Pay Attention To This Key Shift. -- IBD

Peer Comparison

Price change

TransMedics Group Inc Forecast

Price Target

By TipRanks

47.52% upside

12 Months Forecast

Average 100.71 USD  47.52%

High 125 USD

Low 80 USD

Based on 9 Wall Street analysts offering 12 month price targets forTransMedics Group Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

70.33 / 73.68Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

369 / 386 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.